N
RYTM icon

Natixis’s Rhythm Pharmaceuticals RYTM Stock Holding History

Natixis’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-997
Closed -$55.8K – 1167
2024
Q4 		$55.8K Sell
997
-10,190
-91% -$563K ﹤0.01% 873
2024
Q3 		$586K Sell
11,187
-32,764
-75% -$1.57M ﹤0.01% 612
2024
Q2 		$1.8M Buy
43,951
+37,901
+626% +$1.51M 0.01% 430
2024
Q1 		$262K Sell
6,050
-74,450
-92% -$3.26M ﹤0.01% 689
2023
Q4 		$3.7M Buy
+80,500
New +$2.54M 0.03% 327

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Natixis's RYTM Position: Q1 2025 in Review

Natixis sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2025, closing a stake of 997 shares — an estimated $55.8K sold.

Natixis first reported a position in RYTM in Q4 2023 and held it in 5 quarters. The position peaked at $3.7M in Q4 2023. 228 funds tracked by Wall St. Rank hold RYTM as of Q1 2025.

  • Natixis reported no remaining Rhythm Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Natixis sold 997 Rhythm Pharmaceuticals shares in Q1 2025, an estimated $55.8K.
  • Natixis first reported a position in Rhythm Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Natixis's Rhythm Pharmaceuticals position peaked at $3.7M in Q4 2023.
  • 228 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.